EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock suffered a major decline of -10.9% on 10/15/25. The shares closed at $11.73. Moreover, this decline was accompanied by exceptionally high trading volume at 577% of normal. The stock has declined -11.5% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
EyePoint Pharmaceuticals has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. EyePoint Pharmaceuticals has a poor Appreciation Score of 22 but a very high Power Rating of 90, leading to the High Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment